Source comparison
Tesamorelin vs Ipamorelin
Ipamorelin is a growth hormone secretagogue (GHS) that works through a different receptor than tesamorelin. While tesamorelin stimulates GHRH receptors, ipamorelin activates ghrelin receptors (GHS-R) on pituitary somatotrophs. The two mechanisms are complement
This comparison does not assign a generated winner or score.
- Ipamorelin is a growth hormone secretagogue (GHS) that works through a different receptor than tesamorelin. While tesamorelin stimulates GHRH receptors, ipamorelin activates ghrelin receptors (GHS-R) on pituitary somatotrophs. The two mechanisms are complementary, which is why some protocols combine them.
- Ipamorelin has never received FDA approval. It was on the FDA's Category 2 compounding list but was removed in September 2024, similar to CJC-1295. Its availability through compounding pharmacies is uncertain and varies by state.
- The evidence base for ipamorelin consists of Phase 1/2 studies primarily focused on GI motility (post-surgical ileus), not body composition. No randomized controlled trials have measured ipamorelin's effect on visceral fat with CT scan endpoints comparable to the tesamorelin Phase 3 program.
- For a direct comparison, see tesamorelin vs ipamorelin.